PKM2 Regulates Hepatocellular Carcinoma Cell Epithelial-mesenchymal Transition and Migration upon EGFR Activation

  • Fan, Fang-Tian (Department of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine) ;
  • Shen, Cun-Si (Department of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine) ;
  • Tao, Li (Department of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine) ;
  • Tian, Chao (Department of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine) ;
  • Liu, Zhao-Guo (Department of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine) ;
  • Zhu, Zhi-Jie (Department of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine) ;
  • Liu, Yu-Ping (Department of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine) ;
  • Pei, Chang-Song (Department of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine) ;
  • Wu, Hong-Yan (Department of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine) ;
  • Zhang, Lei (Department of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine) ;
  • Wang, Ai-Yun (Department of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine) ;
  • Zheng, Shi-Zhong (Department of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine) ;
  • Huang, Shi-Le (Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center Shreveport) ;
  • Lu, Yin (Department of Pharmacology, College of Pharmacy, Nanjing University of Chinese Medicine)
  • 발행 : 2014.03.01


Pyruvate kinase isozyme type M2 (PKM2) was first found in hepatocellular carcinoma (HCC), and its expression has been thought to correlate with prognosis. A large number of studies have demonstrated that epithelial-mesenchymal transition (EMT) is a crucial event in hepatocellular carcinoma (HCC) and associated metastasis, resulting in enhanced malignancy of HCC. However, the roles of PKM2 in HCC EMT and metastasis remain largely unknown. The present study aimed to determine the effects of PKM2 in EGF-induced HCC EMT and elucidate the molecular mechanisms in vitro. Our results showed that EGF promoted EMT in HCC cell lines as evidenced by altered morphology, expression of EMT-associated markers, and enhanced invasion capacity. Furthermore, the present study also revealed that nuclear translocation of PKM2, which is regulated by the ERK pathway, regulated ${\beta}$-catenin-TCF/LEF-1 transcriptional activity and associated EMT in HCC cell lines. These discoveries provide evidence of novel roles of PKM2 in the progression of HCC and potential therapeutic target for advanced cases.


  1. Al Moustafa AE, Achkhar A, Yasmeen A (2012). EGF-receptor signaling and epithelial-mesenchymal transition in human carcinomas. Front Biosci (Schol Ed), 4, 671-84.
  2. Altekruse SF, McGlynn KA, Dickie LA, Kleiner DE (2012). Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology, 55, 476-82.
  3. Buckley AF, Burgart LJ, Sahai V, Kakar S (2008). Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol, 129, 245-51.
  4. Cano A, Perez-Moreno MA, Rodrigo I, et al (2000). The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol, 2, 76-83.
  5. Eastham AM, Spencer H, Soncin F, et al (2007). Epithelialmesenchymal transition events during human embryonic stem cell differentiation. Cancer Res, 67, 11254-62.
  6. Eggert T, McGlynn KA, Duffy A, et al (2013). Epidemiology of fibrolamellar hepatocellular carcinoma in the USA, 2000-10. Gut.
  7. Fang D, Hawke D, Zheng Y, et al (2007). Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem, 282, 11221-9.
  8. Fischer AN, Fuchs E, Mikula M, et al (2007). PDGF essentially links TGF-beta signaling to nuclear beta-catenin accumulation in hepatocellular carcinoma progression. Oncogene, 26, 3395-405.
  9. Gao X, Wang H, Yang JJ, et al (2012). Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol Cell, 45, 598-609.
  10. Guan CN, Chen XM, Lou HQ, et al (2012). Clinical significance of axin and beta-catenin protein expression in primary hepatocellular carcinomas. Asian Pac J Cancer Prev, 13, 677-81.
  11. Guarino M (2007). Epithelial-mesenchymal transition and tumour invasion. Int J Biochem Cell Biol, 39, 2153-60.
  12. Hu T, Li C (2010). Convergence between Wnt-beta-catenin and EGFR signaling in cancer. Mol Cancer, 9, 236.
  13. Ji H, Wang J, Nika H, et al (2009). EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-catenin from beta-catenin and transactivation of beta-catenin. Mol Cell, 36, 547-59.
  14. Lee J, Kim HK, Han YM, Kim J (2008). Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription. Int J Biochem Cell Biol, 40, 1043-54.
  15. Li SH, Guo ZX, Xiao CZ, et al (2013). Risk factors for early and late intrahepatic recurrence in patients with single hepatocellular carcinoma without macrovascular invasion after curative resection. Asian Pac J Cancer Prev, 14, 4759-63.
  16. Liu D, Aguirre Ghiso J, Estrada Y, Ossowski L (2002). EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell, 1, 445-57.
  17. Llovet JM, Bruix J (2008). Molecular targeted therapies in hepatocellular carcinoma. Hepatology, 48, 1312-27.
  18. Lu Z, Ghosh S, Wang Z, Hunter T (2003). Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell, 4, 499-515.
  19. Luo W, Hu H, Chang R, et al (2011a). Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell, 145, 732-44.
  20. Luo W, Semenza GL (2011b). Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells. Oncotarget, 2, 551-6.
  21. Macintyre AN, Rathmell JC (2011). PKM2 and the tricky balance of growth and energy in cancer. Mol Cell, 42, 713-4.
  22. Maheswaran T, Rushbrook SM (2012). Epithelial-mesenchymal transition and the liver: role in hepatocellular carcinoma and liver fibrosis. J Gastroenterol Hepatol, 27, 418-20.
  23. Mittal S, El-Serag HB (2013). Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol, 47 Suppl, S2-6.
  24. Nejak-Bowen KN, Monga SP (2011). Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad. Semin Cancer Biol, 21, 44-58.
  25. Norsa'adah B, Nurhazalini-Zayani CG (2013). Epidemiology and survival of hepatocellular carcinoma in north-east Peninsular Malaysia. Asian Pac J Cancer Prev, 14, 6955-9.
  26. Ogunwobi OO, Liu C (2011). Hepatocyte growth factor upregulation promotes carcinogenesis and epithelialmesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways. Clin Exp Metastasis, 28, 721-31.
  27. Pan FY, Zhang SZ, Xu N, et al (2010). Beta-catenin signaling involves HGF-enhanced HepG2 scattering through activating MMP-7 transcription. Histochem Cell Biol, 134, 285-95.
  28. Personeni N, Rimassa L, Santoro A (2012). Biomarkers in hepatocellular carcinoma--letter. Clin Cancer Res, 18, 4861.
  29. Spoden GA, Rostek U, Lechner S, et al (2009). Pyruvate kinase isoenzyme M2 is a glycolytic sensor differentially regulating cell proliferation, cell size and apoptotic cell death dependent on glucose supply. Exp Cell Res, 315, 2765-74.
  30. Tamada M, Suematsu M, Saya H (2012). Pyruvate kinase m2: multiple faces for conferring benefits on cancer cells. Clin Cancer Res, 18, 5554-61.
  31. Tan X, Apte U, Micsenyi A, et al (2005). Epidermal growth factor receptor: a novel target of the Wnt/beta-catenin pathway in liver. Gastroenterology, 129, 285-302.
  32. Tanaka M, Masaki Y, Tanaka K, et al (2013). Reduction of fatty acid oxidation and responses to hypoxia correlate with the progression of de-differentiation in HCC. Mol Med Rep, 7, 365-70.
  33. Tsuji T, Ibaragi S, Hu GF (2009). Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res, 69, 7135-9.
  34. Wang LY, Liu YP, Chen LG, et al (2013). Pyruvate kinase M2 plays a dual role on regulation of the EGF/EGFR signaling via E-cadherin-dependent manner in gastric cancer cells. PLoS One, 8, e67542.
  35. Wiangnon S, Kamsa-ard S, Suwanrungruang K, et al (2012). Trends in incidence of hepatocellular carcinoma, 1990-2009, Khon Kaen, Thailand. Asian Pac J Cancer Prev, 13, 1065-8.
  36. Wong N, De Melo J, Tang D (2013). PKM2, a Central Point of Regulation in Cancer Metabolism. Int J Cell Biol, 2013, 242513.
  37. Xu Z, Shen MX, Ma DZ, et al (2003). TGF-beta1-promoted epithelial-to-mesenchymal transformation and cell adhesion contribute to TGF-beta1-enhanced cell migration in SMMC-7721 cells. Cell Res, 13, 343-50.
  38. Yang W, Xia Y, Ji H, et al (2011). Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature, 480, 118-22.
  39. Yang W, Zheng Y, Xia Y, et al (2012). ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat Cell Biol, 14, 1295-304.
  40. Zhang Q, Bai X, Chen W, et al (2013). Wnt/beta-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1alpha signaling. Carcinogenesis.???
  41. Zhou CF, Li XB, Sun H, et al (2012a). Pyruvate kinase type M2 is upregulated in colorectal cancer and promotes proliferation and migration of colon cancer cells. IUBMB Life, 64, 775-82.
  42. Zhou L, Liu C, Meng FD, et al (2012b). Long-term prognosis in hepatocellular carcinoma patients after hepatectomy. Asian Pac J Cancer Prev, 13, 483-6.
  43. Zhu WJ, Huang CY, Li C, et al (2013). Risk factors for early recurrence of hbv-related hepatocellular carcinoma meeting milan criteria after curative resection. Asian Pac J Cancer Prev, 14, 7101-6.

피인용 문헌

  1. Clinical Significance of Joint Detection of Serum VEGF, SIL-2R and HGF in Patients with Primary Hepatocellular Carcinoma before and after Percutaneous Microwave Coagulation Therapy vol.15, pp.11, 2014,
  2. Aquaporin 8 Involvement in Human Cervical Cancer SiHa Migration via the EGFR-Erk1/2 Pathway vol.15, pp.15, 2014,
  3. Crosstalk between EGFR and p53 in Hepatocellular Carcinoma vol.15, pp.19, 2014,
  4. Low Expression of the FoxO4 Gene may Contribute to the Phenomenon of EMT in Non-small Cell Lung Cancer vol.15, pp.9, 2014,
  5. Nuclear translocation of PKM2 modulates astrocyte proliferation via p27 and β-catenin pathway after spinal cord injury vol.14, pp.16, 2015,
  6. Up-Regulation of PKM2 Relates to Retinal Ganglion Cell Apoptosis After Light-Induced Retinal Damage in Adult Rats vol.35, pp.8, 2015,
  7. Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor vol.75, pp.6, 2015,
  8. Redox proteomics screening cellular factors associated with oxidative stress in hepatocarcinogenesis vol.11, pp.3-4, 2016,
  9. C/EBPα Short-Activating RNA Suppresses Metastasis of Hepatocellular Carcinoma through Inhibiting EGFR/β-Catenin Signaling Mediated EMT vol.11, pp.4, 2016,
  10. Leptin promotes epithelial-mesenchymal transition of breast cancer via the upregulation of pyruvate kinase M2 vol.35, pp.1, 2016,
  11. Overexpression of pyruvate kinase M2 predicts a poor prognosis for patients with osteosarcoma vol.37, pp.11, 2016,
  12. Specific tumor-derived CCL2 mediated by pyruvate kinase M2 in colorectal cancer cells contributes to macrophage recruitment in tumor microenvironment vol.39, pp.3, 2017,
  13. Induction of apoptosis by FFJ-5, a novel naphthoquinone compound, occurs via downregulation of PKM2 in A549 and HepG2 cells vol.13, pp.2, 2016,
  14. suppression of sirtuin 3 in pancreatic cancer vol.24, pp.43, 2018,
  15. Signaling Pathways Induced by Leptin during Epithelial–Mesenchymal Transition in Breast Cancer vol.19, pp.11, 2018,
  16. Resveratrol inhibits VEGF-induced angiogenesis in human endothelial cells associated with suppression of aerobic glycolysis via modulation of PKM2 nuclear translocation pp.03051870, 2018,
  17. PKM2-regulated STAT3 promotes esophageal squamous cell carcinoma progression via TGF-β1-induced EMT pp.07302312, 2019,